|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Name of trial** | **Outline of trial** | **Eligible CLL/SCL population** | **Centres open** | **Treatment** | **Website for more information** | **Email** |
| **BGB-11417-101** | BCL2 Inhibitor BGB-11417 (Sonrotoclax);  w or wo Zanubrutinib | Treatment naïve; or relapse/refractory; needing treatment | Wellington; North Shore; ADHB | A Phase 1a/1b Open-Label Dose Escalation and Expansion Study of Sonrotoclax  and Zanubrutinib | <https://clinicaltrials.gov/study/NCT04277637> | [clinicaltrials@beigene.com](mailto:clinicaltrials@beigene.com) |
| **LOXO-BTK-20030** | Pirtobrutinib (LOXO-305) versus Ibrutinib | All patients needing treatment | Dunedin | A Phase 3, Randomised Study | <https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=20969&isClinicalTrial=True> | [info@anzctr.org.au](mailto:info@anzctr.org.au) |
| **AbbVie M14-728** | Venetoclax for Relapsed/refractory CLL/SLL in !7p deletion | Relapsed/refractory CLL/SLL in 17p deletion | Christchurch | Participants with 17p deletion status will receive various doses of Venetoclax once daily | <https://clinicaltrials.gov/study/NCT02966756> | [abbvieclinicaltrials@abbvie.com](mailto:abbvieclinicaltrials@abbvie.com) |
| **Bellwave 01** | Nemtabrutinib Versus Investigator’s Choice of Ibrutinib or Acalabrutinib | Treatment naïve  Needing treatment | North Shore  Middlemore  Waikato | A Phase 3, Randomised Study |  |  |